Literature DB >> 6701462

Mechanism of aprindine induced agranulocytosis: direct toxicity on CFU-C and CFU-GEMM.

M A Boogaerts, M Peters, C Peersman, H Kesteloot, R L Verwilghen.   

Abstract

The in vitro bone marrow growth of 2 patients with aprindine-induced agranulocytosis was studied. Granulocyte-macrophage committed stem cell (CFU-C) growth is inhibited by aprindine in a dose dependent manner. 50% inhibition of CFU-colony growth (TD50) was seen at 5.1 and 3.4 micrograms aprindine/ml medium respectively. The TD50 of control marrow CFU-C was 3.2 micrograms/ml. 100% inhibition was seen at 16 micrograms aprindine/ml, both in patients and controls. Pluripotential stem cell growth (CFU-GEMM) in control marrow was equally inhibited in a dose dependent manner by aprindine, though to a lesser extent (TD50: 9.1 micrograms/ml) and with relative sparing of pure megakaryocyte and erythroid colonies. Co-culturing of patients marrows with their respective acute phase serum did not inhibit CFU-C growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6701462     DOI: 10.1111/j.1600-0609.1984.tb02174.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  4 in total

Review 1.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases.

Authors:  D M Parent-Massin; L Sensébé; M C Léglise; G Guern; C Berthou; C Riché; J F Abgrall
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

3.  The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes.

Authors:  F W Busch; A Tillmann; E W Becker; M Owsianowski; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Risks of rhG-CSF treatment in drug-induced agranulocytosis.

Authors:  H Demuynck; P Zachée; G E Verhoef; M Schetz; G Van den Berghe; P Lauwers; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.